Wes Streeting: £29bn NHS boost ‘substantial’ but reform still needed
A £29bn investment into the National Health System (NHS) is ‘substantial’, but reform of the system is essential to ‘fix …
Post
-
-
Customs simplified: the need to streamline pharma shipments
Pharmaceutical supply chains continue to be disrupted by a range of geopolitical factors, including global conflict, economic uncertainty, and especially …
-
ImmuneWalk presents topline data from Phase I trial’s SAD part of IW-601
ImmuneWalk Therapeutics has presented positive topline data from the single ascending dose (SAD) part of the randomised, first-in-human Phase I …
-
Clinician capacity remains a major bottleneck in UK’s push for cancer trials
While encouraged by revised regulations aimed at boosting UK clinical studies, experts say busy schedules of NHS workers present a …
-
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582, aimed at …
-
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis (PsA) at …
-
Policy changes and digital strategies guide oncology research
Against the backdrop of the recent US Food and Drug Administration’s (FDA) staff cuts and administrative realignment, understanding accelerated approval …
-
Gilead hit with FDA clinical hold for batch of HIV trials
The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV …
-
NHS to receive £29bn funding boost
The UK’s National Health Service (NHS) is receiving a £29bn ($39.1bn) funding boost, reflecting a 3% annual rise on current …
-
MSD’s Enflonsia receives FDA approval for RSV prophylaxis
MSD's Enflonsia (clesrovimab) has received FDA approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) …
-
HepaRegeniX starts dosing subjects in trial of HRX-215 in liver resection patients
German biopharmaceutical company HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver …
-
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis
US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for …
-
Navigating regulatory complexity: Key insights from industry leaders on ICH GP R3 and global compliance
On January 6, 2025, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) issued its …
-
Medable launches programme to enhance eCOA build capabilities in clinical trials
US-based clinical technology provider Medable has launched a programme to supply contract research organisations (CROs) with generative AI-driven, electronic clinical …
-
The state of the biotech industry in 2025
As of April 2025, GlobalData’s Drugs database shows 8,684 investigative drugs under active development by emerging pharmaceutical companies, which are …
